Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AEWS1221||COG||Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479; NSC# 750008; IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma||Pediatric CIRB||Available to Open|
|NRG-HN001||RTOG||Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA5161||ECOG-ACRIN||Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1922||SWOG||Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI In Refractory Small Bowel Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1513||SWOG||Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1406||SWOG||Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|A091401||Alliance||Randomized Phase II Study Of Nivolumab With Or Without Ipilimumab In Patients With Metastatic Or Unresectable Sarcoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA2142||ECOG-ACRIN||Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas||Adult CIRB - Early Phase Emphasis||Available to Open|
|9706||ETCTN||Randomized phase II study to assess the role of Nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (REMAIN Trial)||Adult CIRB - Early Phase Emphasis||Available to Open|
|A221208||Alliance||Randomized Phase II Study: Corticosteroids and Bevacizumab vs. Corticosteroids and Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases||Cancer Prevention and Control CIRB||Available to Open|